(Bloomberg) – An important type of defensive blood cell that persists for at least six months in people after Covid-19, even in asymptomatic people, in a new study may ease concerns about the impaired immunity and its effect on vaccines.
Studies of over 100 people show that they all have T-cell responses against a variety of coronavirus proteins, including the mutant protein used as a marker in many vaccine studies, after half a year. People experiencing symptoms have at least 50% higher levels than people who don’t.
As a handful of vaccines near the finish line, it is unclear how long the protection they will last. A small number of patients have fallen ill with Covid-19 twice.
“This is promising news,”; said Fiona Watt, executive chairman of the UK Medical Research Council. “If a natural infection with a virus can induce a powerful T-cell response, then that means vaccines can do that, too.”
An earlier study, published last month by Imperial College London, has raised concerns that immune defenses may weaken, as it shows the proportion of British people with antibodies declines. time.
Video: The influenza vaccine is specifically designed to enhance immune responses in seniors (ABC 11 Raleigh NC)
Click to expand
Read more: Defense of antibodies against Covid waves over time, Research proposal
T cells are not antibodies. They are white blood cells that can memorize past illnesses, destroy infected cells and activate antibodies to protect the moderation when needed. For example, people infected with another coronavirus that caused the 2003 outbreak of SARS, still have a T-cell response to the disease 17 years later.
The study of a group of immunologists from 17 universities, the UK’s Coronavirus Society of Immunology, has yet to be peer reviewed. This could be the first case of a powerful memory cell against viruses persisting in the long term, the authors say.
None of the patients with blood or serum samples studied were hospitalized with Covid-19.
For more articles like this, please visit us at bloomberg.com
© 2020 Bloomberg LP